Endocrine Abstracts

Introduction: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy approved for the treatment of certain tumors. As the use of ICIs increases, the incidence of rare side effects, called immune-related adverse effects (IRAE), is also increasing, and can affect different systems (gastrointestinal, hepatic, and endocrine among others), with hyponatremia being a possible side effect in patients treated with ICIs. Our objective is to describe one of the few clinical case...

Introduction: Immunotherapy is the oncological treatment whose objective seeks, through the use of immunomodulatory monoclonal antibodies, to block the regulation of the activation and response of T cells, increasing their antitumor response. Pembrolizumab is a new monoclonal antibody directed against the surface protein PD 1, (Programmed Cell Death-1), responsible for the inhibition of the immune response, mediated by T cells, against cancer cells; indicated in the treatment ...